Mark I. Rees
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mark I. Rees has a total of 750 co-authors. Here are the top co-authors by number of shared publications:
- Seo-Kyung Chung
Institute of Life Sciences, Swansea University Medical School, Swansea University, UK
35 shared publications - Rhys Huw Thomas
Faculty of Medical Sciences Newcastle University Newcastle upon Tyne UK
23 shared publications - Robert J. Harvey
School of Health, University of the Sunshine Coast
14 shared publications - Richard Lewis Maxwell Faull
Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand
13 shared publications - Jonathan G. L. Mullins
Structural Bioinformatics Group, Faculty of Medicine, Health and Life Science, Swansea University, Swansea, Wales, United Kingdom
12 shared publications - William Owen Pickrell
Swansea University
11 shared publications
Latest Publications
- Open Access
- 20 April 2017
- Published by Swansea University in International Journal of Population Data Science
- Vol. 1 (1)
Codifying unstructured data: A Natural Language Processing approach to extract rich data from clinical letters
ObjectivesElectronic healthcare records (EHR) are the main data sources that facilitate epidemiology research. Routinely collected data such as primary and secondary care are now easily linked to produce novel and high impact research. There are, however, rich data locked in the free text of clinical letters that are not otherwise translated into EHRs. It is highly desirable to be able to extract this information to strengthen the body of information in existing EHRs. The Swansea Collaborative in Analysis of NLP Research (SCANR) group at Swansea University has been established to evaluate the usage of Natural Language Processing platforms for obtaining new clinical data. To use Clix Enrich to extract SNOMED concepts from a variety of clinical free texts and produce EHRs from the extraction process. Approach SNOMED concepts contain common items of interest such as diagnosis, medication and symptoms, as well as contextual concepts such as historical reference and negation. Clix Enrich uses the SNOMED dictionary to encode clinical free text (pre-co-ordinated) and find contextually correct SNOMED concepts (post co-ordinated). We used Clix Enrich to extract meaningful clinical terms from MS and Epilepsy consultant letters, as well as presenting complaint fields from a Welsh Emergency Department (ED). ResultsWe tailored Clix Enrich to extract a wide variety of clinical terms from each source (fourty texts per source) and validated the extraction accuracy with clinical experts in each domain. Clix Enrich was able to accurately extract the correct diagnosis for MS, Epilepsy and ED attendance (100%, 95% and 80%), dosage and frequency of anti-epileptic medication and MS modifying therapy (90%, 100%) and EDDS score (94%). We note a probable source of discrepancy in extraction accuracy between letter sources in the frequency of abbreviated terms, particularly within the presenting complaint field of the ED sample. ConclusionClix Enrich can be used to accurately extract SNOMED concepts from clinical letters. The resulting datasets are readily available to link to existing EHRs, and can be linked to EHRs that adopt the SNOMED coding structure, or backward compatible hierarchies. Clix Enrich comes with out-of-the-box extraction methods but the optimum way to extract the correct information would be to build in custom queries, thus requiring clinical expertise to validate extraction.
- 20 April 2017
- Published by Swansea University in International Journal of Population Data Science
- Vol. 1 (1)
Open AccessCodifying unstructured data: A Natural Language Processing approach to extract rich data from clinical letters
ObjectivesElectronic healthcare records (EHR) are the main data sources that facilitate epidemiology research. Routinely collected data such as primary and secondary care are now easily linked to produce novel and high impact research. There are, however, rich data locked in the free text of clinical letters that are not otherwise translated into EHRs. It is highly desirable to be able to extract this information to strengthen the body of information in existing EHRs. The Swansea Collaborative in Analysis of NLP Research (SCANR) group at Swansea University has been established to evaluate the usage of Natural Language Processing platforms for obtaining new clinical data. To use Clix Enrich to extract SNOMED concepts from a variety of clinical free texts and produce EHRs from the extraction process. Approach SNOMED concepts contain common items of interest such as diagnosis, medication and symptoms, as well as contextual concepts such as historical reference and negation. Clix Enrich uses the SNOMED dictionary to encode clinical free text (pre-co-ordinated) and find contextually correct SNOMED concepts (post co-ordinated). We used Clix Enrich to extract meaningful clinical terms from MS and Epilepsy consultant letters, as well as presenting complaint fields from a Welsh Emergency Department (ED). ResultsWe tailored Clix Enrich to extract a wide variety of clinical terms from each source (fourty texts per source) and validated the extraction accuracy with clinical experts in each domain. Clix Enrich was able to accurately extract the correct diagnosis for MS, Epilepsy and ED attendance (100%, 95% and 80%), dosage and frequency of anti-epileptic medication and MS modifying therapy (90%, 100%) and EDDS score (94%). We note a probable source of discrepancy in extraction accuracy between letter sources in the frequency of abbreviated terms, particularly within the presenting complaint field of the ED sample. ConclusionClix Enrich can be used to accurately extract SNOMED concepts from clinical letters. The resulting datasets are readily available to link to existing EHRs, and can be linked to EHRs that adopt the SNOMED coding structure, or backward compatible hierarchies. Clix Enrich comes with out-of-the-box extraction methods but the optimum way to extract the correct information would be to build in custom queries, thus requiring clinical expertise to validate extraction.
- 1 April 2017
- Published by Elsevier in Brain and Development
- Vol. 39 (4) , 306-311
Hyperekplexia: Report on phenotype and genotype of 16 Jordanian patients
- 1 April 2017
- Published by Elsevier in Brain and Development
- Vol. 39 (4) , 306-311
Hyperekplexia: Report on phenotype and genotype of 16 Jordanian patients
- Open Access
- 1 February 2017
- Published by Elsevier in The Lancet Neurology
- Vol. 16 (2) , 135-143
Ultra-rare genetic variation in common epilepsies: a case-control sequencing study
- 1 February 2017
- Published by Elsevier in The Lancet Neurology
- Vol. 16 (2) , 135-143
Open AccessUltra-rare genetic variation in common epilepsies: a case-control sequencing study
- Top Cited Papers
- 1 August 2016
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 99 (2) , 287-298
De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies
- 1 August 2016
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 99 (2) , 287-298
Top Cited PapersDe Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies
- Open Access
- 22 June 2016
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 13 (1) , 1-13
Complement is activated in progressive multiple sclerosis cortical grey matter lesions
The symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain and spinal cord. Inflammation is tightly linked with neurodegeneration, and it is the accumulation of neurodegeneration that underlies increasing neurological disability in progressive MS. Determining pathological mechanisms at play in MS grey matter is therefore a key to our understanding of disease progression. We analysed complement expression and activation by immunocytochemistry and in situ hybridisation in frozen or formalin-fixed paraffin-embedded post-mortem tissue blocks from 22 progressive MS cases and made comparisons to inflammatory central nervous system disease and non-neurological disease controls. Expression of the transcript for C1qA was noted in neurons and the activation fragment and opsonin C3b-labelled neurons and glia in the MS cortical and deep grey matter. The density of immunostained cells positive for the classical complement pathway protein C1q and the alternative complement pathway activation fragment Bb was significantly increased in cortical grey matter lesions in comparison to control grey matter. The number of cells immunostained for the membrane attack complex was elevated in cortical lesions, indicating complement activation to completion. The numbers of classical (C1-inhibitor) and alternative (factor H) pathway regulator-positive cells were unchanged between MS and controls, whilst complement anaphylatoxin receptor-bearing microglia in the MS cortex were found closely apposed to cortical neurons. Complement immunopositive neurons displayed an altered nuclear morphology, indicative of cell stress/damage, supporting our finding of significant neurodegeneration in cortical grey matter lesions. Complement is activated in the MS cortical grey matter lesions in areas of elevated numbers of complement receptor-positive microglia and suggests that complement over-activation may contribute to the worsening pathology that underlies the irreversible progression of MS.
- 22 June 2016
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 13 (1) , 1-13
Open AccessComplement is activated in progressive multiple sclerosis cortical grey matter lesions
The symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain and spinal cord. Inflammation is tightly linked with neurodegeneration, and it is the accumulation of neurodegeneration that underlies increasing neurological disability in progressive MS. Determining pathological mechanisms at play in MS grey matter is therefore a key to our understanding of disease progression. We analysed complement expression and activation by immunocytochemistry and in situ hybridisation in frozen or formalin-fixed paraffin-embedded post-mortem tissue blocks from 22 progressive MS cases and made comparisons to inflammatory central nervous system disease and non-neurological disease controls. Expression of the transcript for C1qA was noted in neurons and the activation fragment and opsonin C3b-labelled neurons and glia in the MS cortical and deep grey matter. The density of immunostained cells positive for the classical complement pathway protein C1q and the alternative complement pathway activation fragment Bb was significantly increased in cortical grey matter lesions in comparison to control grey matter. The number of cells immunostained for the membrane attack complex was elevated in cortical lesions, indicating complement activation to completion. The numbers of classical (C1-inhibitor) and alternative (factor H) pathway regulator-positive cells were unchanged between MS and controls, whilst complement anaphylatoxin receptor-bearing microglia in the MS cortex were found closely apposed to cortical neurons. Complement immunopositive neurons displayed an altered nuclear morphology, indicative of cell stress/damage, supporting our finding of significant neurodegeneration in cortical grey matter lesions. Complement is activated in the MS cortical grey matter lesions in areas of elevated numbers of complement receptor-positive microglia and suggests that complement over-activation may contribute to the worsening pathology that underlies the irreversible progression of MS.
- Open Access
- 26 April 2016
- Published by Springer Nature in BMC Medical Genetics
- Vol. 17 (1) , 1-9
Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy
Copy number variants (CNVs) have been linked to neurodevelopmental disorders such as intellectual disability (ID), autism, epilepsy and psychiatric disease. There are few studies of CNVs in patients with both ID and epilepsy. We evaluated the range of rare CNVs found in 80 Welsh patients with ID or developmental delay (DD), and childhood-onset epilepsy. We performed molecular cytogenetic testing by single nucleotide polymorphism array or microarray-based comparative genome hybridisation. 8.8 % (7/80) of the patients had at least one rare CNVs that was considered to be pathogenic or likely pathogenic. The CNVs involved known disease genes (EHMT1, MBD5 and SCN1A) and imbalances in genomic regions associated with neurodevelopmental disorders (16p11.2, 16p13.11 and 2q13). Prompted by the observation of two deletions disrupting SCN1A we undertook further testing of this gene in selected patients. This led to the identification of four pathogenic SCN1A mutations in our cohort. We identified five rare de novo deletions and confirmed the clinical utility of array analysis in patients with ID/DD and childhood-onset epilepsy. This report adds to our clinical understanding of these rare genomic disorders and highlights SCN1A mutations as a cause of ID and epilepsy, which can easily be overlooked in adults.
- 26 April 2016
- Published by Springer Nature in BMC Medical Genetics
- Vol. 17 (1) , 1-9
Open AccessPathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy
Copy number variants (CNVs) have been linked to neurodevelopmental disorders such as intellectual disability (ID), autism, epilepsy and psychiatric disease. There are few studies of CNVs in patients with both ID and epilepsy. We evaluated the range of rare CNVs found in 80 Welsh patients with ID or developmental delay (DD), and childhood-onset epilepsy. We performed molecular cytogenetic testing by single nucleotide polymorphism array or microarray-based comparative genome hybridisation. 8.8 % (7/80) of the patients had at least one rare CNVs that was considered to be pathogenic or likely pathogenic. The CNVs involved known disease genes (EHMT1, MBD5 and SCN1A) and imbalances in genomic regions associated with neurodevelopmental disorders (16p11.2, 16p13.11 and 2q13). Prompted by the observation of two deletions disrupting SCN1A we undertook further testing of this gene in selected patients. This led to the identification of four pathogenic SCN1A mutations in our cohort. We identified five rare de novo deletions and confirmed the clinical utility of array analysis in patients with ID/DD and childhood-onset epilepsy. This report adds to our clinical understanding of these rare genomic disorders and highlights SCN1A mutations as a cause of ID and epilepsy, which can easily be overlooked in adults.
- Open Access
- 1 September 2015
- Published by Elsevier in EBioMedicine
- Vol. 2 (9) , 1063-1070
Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy
- 1 September 2015
- Published by Elsevier in EBioMedicine
- Vol. 2 (9) , 1063-1070
Open AccessGenome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy
- Open Access
- 30 June 2015
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (18) , 5313-5325
Recognizable cerebellar dysplasia associated with mutations in multiple tubulin genes
Mutations in alpha- and beta-tubulins are increasingly recognized as a major cause of malformations of cortical development (MCD), typically lissencephaly, pachygyria and polymicrogyria; however, sequencing tubulin genes in large cohorts of MCD patients has detected tubulin mutations in only 1–13%. We identified patients with a highly characteristic cerebellar dysplasia but without lissencephaly, pachygyria and polymicrogyria typically associated with tubulin mutations. Remarkably, in seven of nine patients (78%), targeted sequencing revealed mutations in three different tubulin genes (TUBA1A, TUBB2B and TUBB3), occurring de novo or inherited from a mosaic parent. Careful re-review of the cortical phenotype on brain imaging revealed only an irregular pattern of gyri and sulci, for which we propose the term tubulinopathy-related dysgyria. Basal ganglia (100%) and brainstem dysplasia (80%) were common features. On the basis of in silico structural predictions, the mutations affect amino acids in diverse regions of the alpha-/beta-tubulin heterodimer, including the nucleotide binding pocket. Cell-based assays of tubulin dynamics reveal various effects of the mutations on incorporation into microtubules: TUBB3 p.Glu288Lys and p.Pro357Leu do not incorporate into microtubules at all, whereas TUBB2B p.Gly13Ala shows reduced incorporation and TUBA1A p.Arg214His incorporates fully, but at a slower rate than wild-type. The broad range of effects on microtubule incorporation is at odds with the highly stereotypical clinical phenotype, supporting differential roles for the three tubulin genes involved. Identifying this highly characteristic phenotype is important due to the low recurrence risk compared with the other (recessive) cerebellar dysplasias and the apparent lack of non-neurological medical issues.
- 30 June 2015
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (18) , 5313-5325
Open AccessRecognizable cerebellar dysplasia associated with mutations in multiple tubulin genes
Mutations in alpha- and beta-tubulins are increasingly recognized as a major cause of malformations of cortical development (MCD), typically lissencephaly, pachygyria and polymicrogyria; however, sequencing tubulin genes in large cohorts of MCD patients has detected tubulin mutations in only 1–13%. We identified patients with a highly characteristic cerebellar dysplasia but without lissencephaly, pachygyria and polymicrogyria typically associated with tubulin mutations. Remarkably, in seven of nine patients (78%), targeted sequencing revealed mutations in three different tubulin genes (TUBA1A, TUBB2B and TUBB3), occurring de novo or inherited from a mosaic parent. Careful re-review of the cortical phenotype on brain imaging revealed only an irregular pattern of gyri and sulci, for which we propose the term tubulinopathy-related dysgyria. Basal ganglia (100%) and brainstem dysplasia (80%) were common features. On the basis of in silico structural predictions, the mutations affect amino acids in diverse regions of the alpha-/beta-tubulin heterodimer, including the nucleotide binding pocket. Cell-based assays of tubulin dynamics reveal various effects of the mutations on incorporation into microtubules: TUBB3 p.Glu288Lys and p.Pro357Leu do not incorporate into microtubules at all, whereas TUBB2B p.Gly13Ala shows reduced incorporation and TUBA1A p.Arg214His incorporates fully, but at a slower rate than wild-type. The broad range of effects on microtubule incorporation is at odds with the highly stereotypical clinical phenotype, supporting differential roles for the three tubulin genes involved. Identifying this highly characteristic phenotype is important due to the low recurrence risk compared with the other (recessive) cerebellar dysplasias and the apparent lack of non-neurological medical issues.
Epilepsy and deprivation, a data linkage study
Summary: Objective: To investigate whether the link between epilepsy and deprivation is due to factors associated with deprivation (social causation) or factors associated with a diagnosis of epilepsy (social drift).Methods: We reviewed electronic primary health care records from 2004 to 2010, identifying prevalent and incident cases of epilepsy and recording linked deprivation scores. Logistic and Poisson regression models were used to calculate odds ratios and incidence rate ratios. The change in deprivation was measured 10 years after the initial diagnosis of epilepsy for a cohort of people.Results: Between 2004 and 2010, 8.1 million patient‐years of records were reviewed. Epilepsy prevalence and incidence were significantly associated with deprivation. Epilepsy prevalence ranged from 1.13% (1.07–1.19%) in the most deprived decile to 0.49% (0.45–0.53%) in the least deprived decile (adjusted odds ratio 0.92, p < 0.001). Epilepsy incidence ranged from 40/100,000 per year in the most deprived decile to 19/100,000 per year in the least deprived decile (adjusted incidence rate ratio 0.94, p < 0.001). There was no statistically significant change in deprivation index decile 10 years after a new diagnosis of epilepsy (mean difference −0.04, p = 0.85).Significance: Epilepsy prevalence and incidence are strongly associated with deprivation; the deprivation score remains unchanged 10 years after a diagnosis of epilepsy. These findings suggest that increasing rates of epilepsy in deprived areas are more likely explained by social causation than by social drift. The nature of the association between incident epilepsy and social deprivation needs further exploration.
Epilepsy and deprivation, a data linkage study
Summary: Objective: To investigate whether the link between epilepsy and deprivation is due to factors associated with deprivation (social causation) or factors associated with a diagnosis of epilepsy (social drift).Methods: We reviewed electronic primary health care records from 2004 to 2010, identifying prevalent and incident cases of epilepsy and recording linked deprivation scores. Logistic and Poisson regression models were used to calculate odds ratios and incidence rate ratios. The change in deprivation was measured 10 years after the initial diagnosis of epilepsy for a cohort of people.Results: Between 2004 and 2010, 8.1 million patient‐years of records were reviewed. Epilepsy prevalence and incidence were significantly associated with deprivation. Epilepsy prevalence ranged from 1.13% (1.07–1.19%) in the most deprived decile to 0.49% (0.45–0.53%) in the least deprived decile (adjusted odds ratio 0.92, p < 0.001). Epilepsy incidence ranged from 40/100,000 per year in the most deprived decile to 19/100,000 per year in the least deprived decile (adjusted incidence rate ratio 0.94, p < 0.001). There was no statistically significant change in deprivation index decile 10 years after a new diagnosis of epilepsy (mean difference −0.04, p = 0.85).Significance: Epilepsy prevalence and incidence are strongly associated with deprivation; the deprivation score remains unchanged 10 years after a diagnosis of epilepsy. These findings suggest that increasing rates of epilepsy in deprived areas are more likely explained by social causation than by social drift. The nature of the association between incident epilepsy and social deprivation needs further exploration.
- 1 September 2014
- Published by Wiley in Epileptic Disorders
- Vol. 16 (3) , 354-357
Neonatal hyperekplexia with homozygous p.R392H mutation in GLRA1
Hyperekplexia is a rare neurogenetic disorder, frequently misdiagnosed in neonates with a risk of apnoea, asphyxia, and sudden infant death. We present video sequences of a male newborn, admitted on the second day of life to the neonatal intensive care unit, due to tonic‐clonic movements. Following clinical and paraclinical investigations, a final diagnosis of hyperekplexia was made. Genetic analysis revealed a homozygous mutation in GLRA1 resulting in a R392H amino acid substitution and altered receptor dynamics, as indicated from previous work. The infant showed a marked improvement of the startle response and muscle hypertonia with clonazepam which is a strong clinical feature of GLRA1‐mediated hyperekplexia. [Published with video sequences]
- 1 September 2014
- Published by Wiley in Epileptic Disorders
- Vol. 16 (3) , 354-357
Neonatal hyperekplexia with homozygous p.R392H mutation in GLRA1
Hyperekplexia is a rare neurogenetic disorder, frequently misdiagnosed in neonates with a risk of apnoea, asphyxia, and sudden infant death. We present video sequences of a male newborn, admitted on the second day of life to the neonatal intensive care unit, due to tonic‐clonic movements. Following clinical and paraclinical investigations, a final diagnosis of hyperekplexia was made. Genetic analysis revealed a homozygous mutation in GLRA1 resulting in a R392H amino acid substitution and altered receptor dynamics, as indicated from previous work. The infant showed a marked improvement of the startle response and muscle hypertonia with clonazepam which is a strong clinical feature of GLRA1‐mediated hyperekplexia. [Published with video sequences]